Xiangxue Pharmaceutical (300147) - Net Assets
Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has net assets worth CN¥-237.24 Million CNY (≈ $-34.72 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.65 Billion ≈ $973.38 Million USD) and total liabilities (CN¥6.89 Billion ≈ $1.01 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Xiangxue Pharmaceutical to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥-237.24 Million |
| % of Total Assets | -3.57% |
| Annual Growth Rate | -7.85% |
| 5-Year Change | -98.83% |
| 10-Year Change | -98.81% |
| Growth Volatility | 79.22 |
Xiangxue Pharmaceutical - Net Assets Trend (2007–2025)
This chart illustrates how Xiangxue Pharmaceutical's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 300147 market cap overview.
Annual Net Assets for Xiangxue Pharmaceutical (2007–2025)
The table below shows the annual net assets of Xiangxue Pharmaceutical from 2007 to 2025. Also explore net asset momentum of Xiangxue Pharmaceutical to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥43.95 Million ≈ $6.43 Million |
-96.95% |
| 2024-12-31 | CN¥1.44 Billion ≈ $210.55 Million |
-37.80% |
| 2023-12-31 | CN¥2.31 Billion ≈ $338.50 Million |
-17.92% |
| 2022-12-31 | CN¥2.82 Billion ≈ $412.39 Million |
-25.00% |
| 2021-12-31 | CN¥3.76 Billion ≈ $549.88 Million |
-11.64% |
| 2020-12-31 | CN¥4.25 Billion ≈ $622.35 Million |
+3.44% |
| 2019-12-31 | CN¥4.11 Billion ≈ $601.66 Million |
+2.48% |
| 2018-12-31 | CN¥4.01 Billion ≈ $587.12 Million |
+3.31% |
| 2017-12-31 | CN¥3.88 Billion ≈ $568.31 Million |
+5.41% |
| 2016-12-31 | CN¥3.68 Billion ≈ $539.14 Million |
+3.90% |
| 2015-12-31 | CN¥3.55 Billion ≈ $518.89 Million |
+89.50% |
| 2014-12-31 | CN¥1.87 Billion ≈ $273.82 Million |
+9.43% |
| 2013-12-31 | CN¥1.71 Billion ≈ $250.23 Million |
+11.29% |
| 2012-12-31 | CN¥1.54 Billion ≈ $224.85 Million |
+8.29% |
| 2011-12-31 | CN¥1.42 Billion ≈ $207.64 Million |
+3.53% |
| 2010-12-31 | CN¥1.37 Billion ≈ $200.56 Million |
+305.96% |
| 2009-12-31 | CN¥337.62 Million ≈ $49.41 Million |
+71.79% |
| 2008-12-31 | CN¥196.54 Million ≈ $28.76 Million |
+2.66% |
| 2007-12-31 | CN¥191.45 Million ≈ $28.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Xiangxue Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4537.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.87 Billion | % |
| Total Equity | CN¥-360.32 Million | 100.00% |
Xiangxue Pharmaceutical Competitors by Market Cap
The table below lists competitors of Xiangxue Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEC Electric Mach Co Ltd
SHG:603988
|
$631.90 Million |
|
Rongsheng Paper
SHG:603165
|
$632.09 Million |
|
TrueLight
TWO:3234
|
$632.17 Million |
|
Lotte Tour Dev
KO:032350
|
$632.23 Million |
|
ECN Capital Corp
TO:ECN
|
$631.79 Million |
|
Hangzhou Shenhao Technology Co Ltd
SHE:300853
|
$631.77 Million |
|
Hainan Haiqi Transportation Group Co Ltd
SHG:603069
|
$631.65 Million |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871
|
$631.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xiangxue Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,054,899,213 to -360,324,172, a change of -1,415,223,385 (-134.2%).
- Net loss of 1,392,170,794 reduced equity.
- Dividend payments of 5,839,272 reduced retained earnings.
- Other comprehensive income decreased equity by 86,437,080.
- Other factors increased equity by 69,223,761.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-1.39 Billion | -386.37% |
| Dividends Paid | CN¥5.84 Million | -1.62% |
| Other Comprehensive Income | CN¥-86.44 Million | -23.99% |
| Other Changes | CN¥69.22 Million | +19.21% |
| Total Change | CN¥- | -134.16% |
Book Value vs Market Value Analysis
This analysis compares Xiangxue Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.45 | CN¥6.53 | x |
| 2008-12-31 | CN¥0.46 | CN¥6.53 | x |
| 2009-12-31 | CN¥0.81 | CN¥6.53 | x |
| 2010-12-31 | CN¥2.97 | CN¥6.53 | x |
| 2011-12-31 | CN¥2.29 | CN¥6.53 | x |
| 2012-12-31 | CN¥2.47 | CN¥6.53 | x |
| 2013-12-31 | CN¥3.36 | CN¥6.53 | x |
| 2014-12-31 | CN¥2.84 | CN¥6.53 | x |
| 2015-12-31 | CN¥5.38 | CN¥6.53 | x |
| 2016-12-31 | CN¥5.14 | CN¥6.53 | x |
| 2017-12-31 | CN¥5.25 | CN¥6.53 | x |
| 2018-12-31 | CN¥5.47 | CN¥6.53 | x |
| 2019-12-31 | CN¥5.34 | CN¥6.53 | x |
| 2020-12-31 | CN¥5.52 | CN¥6.53 | x |
| 2021-12-31 | CN¥4.47 | CN¥6.53 | x |
| 2022-12-31 | CN¥3.65 | CN¥6.53 | x |
| 2023-12-31 | CN¥2.92 | CN¥6.53 | x |
| 2024-12-31 | CN¥1.60 | CN¥6.53 | x |
| 2025-12-31 | CN¥-0.54 | CN¥6.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xiangxue Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -87.26%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-2.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 17.20% | 11.92% | 0.47x | 3.09x | CN¥12.89 Million |
| 2008 | 19.74% | 12.19% | 0.53x | 3.03x | CN¥17.74 Million |
| 2009 | 15.88% | 13.45% | 0.54x | 2.18x | CN¥18.86 Million |
| 2010 | 5.51% | 14.45% | 0.28x | 1.37x | CN¥-60.56 Million |
| 2011 | 5.99% | 13.55% | 0.32x | 1.38x | CN¥-55.92 Million |
| 2012 | 7.22% | 13.38% | 0.27x | 1.99x | CN¥-41.16 Million |
| 2013 | 9.86% | 12.55% | 0.36x | 2.16x | CN¥-2.30 Million |
| 2014 | 11.28% | 12.91% | 0.42x | 2.06x | CN¥22.41 Million |
| 2015 | 5.20% | 12.11% | 0.31x | 1.37x | CN¥-163.47 Million |
| 2016 | 1.94% | 3.55% | 0.23x | 2.35x | CN¥-273.64 Million |
| 2017 | 1.90% | 3.01% | 0.23x | 2.73x | CN¥-280.25 Million |
| 2018 | 1.65% | 2.25% | 0.29x | 2.51x | CN¥-286.62 Million |
| 2019 | 2.19% | 2.75% | 0.33x | 2.43x | CN¥-272.33 Million |
| 2020 | 2.72% | 3.20% | 0.31x | 2.70x | CN¥-263.23 Million |
| 2021 | -23.37% | -23.18% | 0.26x | 3.86x | CN¥-983.02 Million |
| 2022 | -22.04% | -24.24% | 0.23x | 3.89x | CN¥-770.57 Million |
| 2023 | -20.21% | -16.92% | 0.28x | 4.30x | CN¥-581.43 Million |
| 2024 | -81.39% | -46.19% | 0.25x | 7.11x | CN¥-964.05 Million |
| 2025 | 0.00% | -87.26% | 0.24x | 0.00x | CN¥-1.36 Billion |
Industry Comparison
This section compares Xiangxue Pharmaceutical's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,630,540,352
- Average return on equity (ROE) among peers: 6.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xiangxue Pharmaceutical (300147) | CN¥-237.24 Million | 17.20% | N/A | $631.88 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $89.81 Million | 2.75% | 1.57x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $56.30 Million | 0.00% | 2.39x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $445.86 Million | 0.46% | 0.45x | $483.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $712.38 Million | 3.28% | 0.06x | $575.51 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.67 Billion | 2.43% | 1.21x | $1.61 Billion |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $3.46 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $25.90 Billion | 5.00% | 0.05x | $4.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.44 Billion | 2.86% | 0.17x | $428.14 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.62 Billion |
About Xiangxue Pharmaceutical
Xiangxue Pharmaceutical Co.,Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet sa… Read more